pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,673 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1788Endpoints1392Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Supreme Court to hear arguments on generic fish‑oil pill case, industry watches
    The U.S. Supreme Court is set to hear arguments this week on a case involving a prescription‑strength pill derived from fish oil. The dispute centers on whether the product qualifies as a generic…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF from Chinese biotech
    BeOne Medicines, formerly known as BeiGene, announced a licensing agreement with a Chinese biotechnology firm to obtain rights to an experimental trispecific antibody. The antibody is engineered t…
    Endpoints · 6mo agoDealPositive↗ source
← prev
page 106 of 107
next →
113
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
  • Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseases
    Coultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…
    Endpoints · 6mo agoDealPositive↗ source
  • Boehringer's obesity injection shows 17% weight loss after 18 months, comparable to Wegovy but below Zepbound
    Boehringer Ingelheim, together with Zealand, released data from a late‑stage study of its experimental obesity injection. The trial followed patients for roughly a year and a half. Participants on…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • AI-driven admin tech continues to dominate health-tech funding landscape
    The article notes that administrative technology remains the leading segment within health‑tech investment. Startups that apply artificial intelligence to automate routine tasks such as patient fol…
    Endpoints · 6mo agoPositive↗ source
  • Eli Lilly announces second partnership this year to advance recombinase-based gene editing
    Eli Lilly has entered a second partnership this year aimed at developing recombinase-based gene‑editing technologies. The collaboration follows earlier efforts to explore enzymes that can precisely…
    Endpoints · 6mo agoDealPositive↗ source
  • Rocket Pharmaceuticals sells pediatric disease priority review voucher for $180 million; Oruka eyes $500 million offering
    Rocket Pharmaceuticals, a New Jersey gene-therapy company, sold its priority review voucher for a rare pediatric disease to an undisclosed buyer for $180 million. The voucher was earned after the…
    Endpoints · 6mo agoDealNeutral↗ source
  • Devoted Health reports first revenue decline in 2025 amid Medicare Advantage turbulence
    Devoted Health, a startup offering Medicare Advantage plans, saw its revenue and membership drop in 2025, marking the first decline since it began offering plans seven years ago. The downturn refl…
    Endpoints · 6mo agoNegative↗ source
  • Adaptyv Bio shares results from its latest AI-driven protein design contest
    Adaptyv Bio, a biotech firm focused on protein engineering, released the outcomes of its newest competition that tests how well artificial‑intelligence models can create novel proteins. The challe…
    Endpoints · 6mo agoNeutral↗ source
  • Intellia's in-body CRISPR therapy achieves first Phase 3 success
    Intellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Sun Pharma to acquire Organon for $11.75 billion in all-cash deal
    Indian pharmaceutical company Sun Pharma announced it will purchase Organon, a company focused on women's health and biosimilars that was spun out of Merck in 2021. The transaction is an all-cash…
    Endpoints · 6mo agoDealPositive↗ source
  • Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedema
    Intellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer deal
    Eli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…
    Endpoints · 6mo agoDealPositive↗ source
  • Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock drop
    Compass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
    Endpoints · 6mo agoNegative readoutNegative↗ source
  • Erasca releases early-stage RAS drug data amid legal dispute with Revolution Medicines
    Erasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…
    Endpoints · 6mo agoNeutral↗ source
  • Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMA
    Thermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg. The transaction is valued at $1.075 bi…
    Endpoints · 6mo agoDealNeutral↗ source
  • Oruka Therapeutics reports Phase 2 psoriasis results with 63% of patients showing plaque improvement
    Oruka Therapeutics announced results from its Phase 2 trial in moderate to severe plaque psoriasis. The study enrolled 63 patients and 40 of them, about 63.5%, achieved the predefined level of ski…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from Atommap
    Fathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artifici…
    Endpoints · 6mo agoDealPositive↗ source
  • Veradermics reports positive Phase 2/3 results for oral Rogaine in men with pattern hair loss
    Veradermics, a biotech that recently went public, announced that its oral formulation of Rogaine met the primary endpoints in a late-stage Phase 2/3 trial. The study enrolled men with mild-to-mode…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Revolution Medicines threatens lawsuit against Erasca over RAS drug patent and efficacy claims
    Earlier this month a newly announced cancer therapy generated strong interest from patients and investors. The drug, which targets the RAS pathway, was highlighted for its potential impact on oncol…
    Endpoints · 6mo agoRegulatoryNegative↗ source
  • Utah doctors urge state to suspend Doctronic AI prescription-refill program
    Utah medical licensing board members have asked the state to halt a temporary program that lets startup Doctronic use artificial intelligence to refill prescriptions. The board says the AI-driven…
    Endpoints · 6mo agoRegulatoryNegative↗ source
  • UK biotech funding shows early recovery after mid-2025 lull, BIA reports
    The BioIndustry Association released data indicating that equity financing for UK biotech companies is beginning to rise again in early 2026. The trend follows a slowdown that began in mid-2025, w…
    Endpoints · 6mo agoPositive↗ source
  • Endpoints Weekly celebrates Neal Awards while previewing Sanofi, Lilly and RevMed updates
    Endpoints Weekly released its latest edition on April 25, 2026, noting a celebratory tone after the publication earned three Neal Awards for B2B journalism excellence. The issue highlights several…
    Endpoints · 6mo agoPositive↗ source
  • Sanofi’s tolebrutinib receives EU CHMP endorsement for specific multiple sclerosis patients despite US FDA setback
    Sanofi's BTK inhibitor tolebrutinib is moving toward approval in the European Union for a subset of multiple sclerosis patients. The Committee for Medicinal Products for Human Use (CHMP) of the Eu…
    Endpoints · 6mo agoRegulatoryPositive↗ source
  • Avalyn Pharma targets $182M IPO as WHO prequalifies Novartis malaria drug
    Avalyn Pharma announced plans for an initial public offering that could raise about $182 million in net proceeds. The company is developing inhaled formulations of drugs already approved for pulmon…
    Endpoints · 6mo agoDealNeutral↗ source